3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Phase 2
1
Status
Recruiting
2
Terminated
1
Completed
1
Sponsor Class
OTHER
5
INDUSTRY
4
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
NET
3
Endocrine
3
Gastrointestinal
1
Conditions
Breast Neoplasms
41
Carcinoma, Renal Cell
32
Neuroendocrine Tumors
15
Neoplasms
12
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
8
Carcinoma
7
Tuberous Sclerosis
6
Kidney Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoid Tumor
5
Lymphoma
4
Adenoma, Islet Cell
4
Stomach Neoplasms
3
Recurrence
3
Pancreatic Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell
3
Lymphangioleiomyomatosis
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Angiomyolipoma
3
Adenocarcinoma
3
von Hippel-Lindau Disease
2
Triple Negative Breast Neoplasms
2
Seizures
2
Neuroectodermal Tumors, Primitive
2
Lymphoproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Interventions
Sunitinib
4
Everolimus
4
Endoscopic Ultrasound-Guided Fine Needle Aspiration
2
napabucasin
1
lanreotide
1
irinotecan sucrosofate
1
belzutifan
1
Taxes
1
Paclitaxel
1
Oxaliplatin
1
Octreotide
1
Leucovorin
1
LY2940680
1
Irinotecan
1
Gemcitabine
1
Fluorouracil
1
Albumin-Bound Paclitaxel
1
90Y-octreotide, DOTA-Tyr(3)-
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenoma, Islet Cell
×
Everolimus
×
Clear all
NCT06943755
2026-04-17
STELLAR-311
Exelixis
Phase 2/3
Recruiting
440 enrolled
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled
NCT02264665
2023-11-13
OPALINE
Pfizer
Completed
144 enrolled
26 charts
NCT01374451
2016-12-20
COOPERATE-2
Novartis
Phase 2
Terminated
160 enrolled
17 charts